PL2049566T3 - Swoiste dla miejsca monokoniugaty G-CSF - Google Patents
Swoiste dla miejsca monokoniugaty G-CSFInfo
- Publication number
- PL2049566T3 PL2049566T3 PL07788029T PL07788029T PL2049566T3 PL 2049566 T3 PL2049566 T3 PL 2049566T3 PL 07788029 T PL07788029 T PL 07788029T PL 07788029 T PL07788029 T PL 07788029T PL 2049566 T3 PL2049566 T3 PL 2049566T3
- Authority
- PL
- Poland
- Prior art keywords
- conjugates
- site
- csf
- specific mono
- analogues
- Prior art date
Links
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 abstract 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 abstract 2
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 abstract 1
- 108060008539 Transglutaminase Proteins 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 210000000440 neutrophil Anatomy 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 102000003601 transglutaminase Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001624A ITMI20061624A1 (it) | 2006-08-11 | 2006-08-11 | Mono-coniugati sito-specifici di g-csf |
| EP07788029A EP2049566B1 (en) | 2006-08-11 | 2007-07-30 | G-csf site-specific mono-conjugates |
| PCT/EP2007/057824 WO2008017603A1 (en) | 2006-08-11 | 2007-07-30 | G-csf site-specific mono-conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2049566T3 true PL2049566T3 (pl) | 2010-06-30 |
Family
ID=38510395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07788029T PL2049566T3 (pl) | 2006-08-11 | 2007-07-30 | Swoiste dla miejsca monokoniugaty G-CSF |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7893019B2 (pl) |
| EP (1) | EP2049566B1 (pl) |
| JP (1) | JP5336372B2 (pl) |
| AT (1) | ATE453666T1 (pl) |
| CA (1) | CA2660615A1 (pl) |
| DE (1) | DE602007004120D1 (pl) |
| ES (1) | ES2338605T3 (pl) |
| IT (1) | ITMI20061624A1 (pl) |
| PL (1) | PL2049566T3 (pl) |
| WO (1) | WO2008017603A1 (pl) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214660B2 (en) * | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US7173003B2 (en) * | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| US8008252B2 (en) | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
| US7157277B2 (en) * | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| MXPA04012496A (es) * | 2002-06-21 | 2005-09-12 | Novo Nordisk Healthcare Ag | Glicoformos del factor vii pegilados. |
| JP2006523211A (ja) * | 2003-03-14 | 2006-10-12 | ネオス テクノロジーズ インコーポレイテッド | 分岐水溶性ポリマーとその複合物 |
| NZ542586A (en) * | 2003-04-09 | 2009-11-27 | Biogenerix Ag | Method of forming a covalent conjugate between a G-CSF peptide and PEG |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| WO2006127896A2 (en) | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated factor ix |
| AU2004240553A1 (en) * | 2003-05-09 | 2004-12-02 | Neose Technologies, Inc. | Compositions and methods for the preparation of human growth hormone glycosylation mutants |
| US9005625B2 (en) * | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
| US7405198B2 (en) * | 2003-11-24 | 2008-07-29 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US8633157B2 (en) * | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US20080015142A1 (en) * | 2003-12-03 | 2008-01-17 | Defrees Shawn | Glycopegylated Follicle Stimulating Hormone |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| WO2005055946A2 (en) * | 2003-12-03 | 2005-06-23 | Neose Technologies, Inc. | Glycopegylated granulocyte colony stimulating factor |
| US7338933B2 (en) * | 2004-01-08 | 2008-03-04 | Neose Technologies, Inc. | O-linked glycosylation of peptides |
| WO2006010143A2 (en) | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1] |
| US20090292110A1 (en) * | 2004-07-23 | 2009-11-26 | Defrees Shawn | Enzymatic modification of glycopeptides |
| EP1799249A2 (en) * | 2004-09-10 | 2007-06-27 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
| EP3061461A1 (en) | 2004-10-29 | 2016-08-31 | ratiopharm GmbH | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| US9029331B2 (en) * | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| EP1871795A4 (en) | 2005-04-08 | 2010-03-31 | Biogenerix Ag | COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE |
| US20110003744A1 (en) * | 2005-05-25 | 2011-01-06 | Novo Nordisk A/S | Glycopegylated Erythropoietin Formulations |
| US20070105755A1 (en) * | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| WO2007056191A2 (en) * | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
| US20080242607A1 (en) * | 2006-07-21 | 2008-10-02 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
| US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
| BRPI0717505B8 (pt) * | 2006-10-04 | 2021-05-25 | Novo Nordisk As | conjugado de peptídeo e formulação farmacêutica |
| CN101796063B (zh) * | 2007-04-03 | 2017-03-22 | 拉蒂奥法姆有限责任公司 | 使用糖聚乙二醇化g‑csf的治疗方法 |
| US20110177029A1 (en) * | 2007-06-04 | 2011-07-21 | Novo Nordisk A/S | O-linked glycosylation using n-acetylglucosaminyl transferases |
| US9493499B2 (en) * | 2007-06-12 | 2016-11-15 | Novo Nordisk A/S | Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography |
| US7968811B2 (en) * | 2007-06-29 | 2011-06-28 | Harley-Davidson Motor Company Group, Inc. | Integrated ignition and key switch |
| DK2197919T3 (da) | 2007-08-27 | 2014-07-07 | Ratiopharm Gmbh | Flydende formulering af g-csf-konjugat |
| US8207112B2 (en) * | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
| JP5647899B2 (ja) * | 2008-01-08 | 2015-01-07 | ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ | オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化 |
| DK2257311T3 (da) | 2008-02-27 | 2014-06-30 | Novo Nordisk As | Konjugerede Faktor VIII-Molekyler |
| MX2011000859A (es) * | 2008-07-23 | 2011-02-24 | Ambrx Inc | Polipeptidos g-csf bovinos modificados y sus usos. |
| IT1392655B1 (it) * | 2008-11-20 | 2012-03-16 | Bio Ker S R L | Site-specific monoconjugated insulinotropic glp-1 peptides. |
| TWI480288B (zh) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | 牛顆粒細胞群落刺激因子及其變體之調配物 |
| CN107043339B (zh) | 2011-07-19 | 2019-09-06 | 希默赛生物技术有限责任公司 | 新交联试剂、大分子、治疗用偶联物及其合成方法 |
| ITMI20122097A1 (it) * | 2012-12-10 | 2014-06-11 | Bio Ker S R L | Procedimento per la preparazione di proteine terapeutiche peghilate ad elevato grado di purezza |
| EP3050570A1 (en) * | 2015-01-31 | 2016-08-03 | Neurovision Pharma GmbH | Pharmaceutical composition consisting of a combination of G-CSF with GM-CSF |
| EP3319936B1 (en) | 2015-07-12 | 2025-12-17 | Hangzhou Dac Biotech Co., Ltd. | Bridge linkers for conjugation of cell-binding molecules |
| US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
| AU2016429272A1 (en) | 2016-11-14 | 2019-05-02 | Hangzhou Dac Biotech Co., Ltd. | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers |
| JP2022540395A (ja) | 2019-06-29 | 2022-09-15 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． | 細胞結合性分子－チューブリシン誘導体共役体及びその調製方法 |
| CN112316120A (zh) * | 2019-08-05 | 2021-02-05 | 天津派格生物技术有限公司 | 使用低动员型g-csf有效且安全治疗粒细胞减少症的方法 |
| TR201917122A2 (tr) * | 2019-11-05 | 2021-05-21 | Hacettepe Ueniversitesi | Protei̇n i̇laçlarin enzi̇mati̇k yolla bi̇yopoli̇merlerle konjugasyonu |
| WO2021188869A2 (en) * | 2020-03-20 | 2021-09-23 | Amgen Inc. | Determination of free n-terminus of pegfilgrastim using an acid protease |
| CN117980327A (zh) | 2021-11-03 | 2024-05-03 | 杭州多禧生物科技有限公司 | 抗体的特异性偶联 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4847325A (en) | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
| CA1340810C (en) | 1988-03-31 | 1999-11-02 | Motoo Yamasaki | Polypeptide derivatives of human granulocyte colony stimulating factor |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| EP0785276A4 (en) | 1994-09-29 | 2002-01-09 | Ajinomoto Kk | MODIFICATION OF A PEPTIDE AND A PROTEIN |
| US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| HK1049673A1 (zh) | 1999-01-29 | 2003-05-23 | 霍夫曼-拉罗奇有限公司 | Gcsf缀合物 |
| DE10011926A1 (de) * | 2000-01-14 | 2001-08-02 | Deutsches Krebsforsch | Genetisch veränderte Fibroblastenzellen |
| ATE468862T1 (de) * | 2001-07-11 | 2010-06-15 | Maxygen Inc | G-csf konjugate |
| JPWO2004101619A1 (ja) * | 2003-05-15 | 2006-10-26 | 塩野義製薬株式会社 | 機能的糖ペプチドの合理的設計および合成 |
| EP1586334A1 (en) | 2004-04-15 | 2005-10-19 | TRASTEC scpa | G-CSF conjugates with peg |
| US20060036080A1 (en) | 2004-07-16 | 2006-02-16 | Bossard Mary J | Conjugates of GM-CSF moiety and a polymer |
-
2006
- 2006-08-11 IT IT001624A patent/ITMI20061624A1/it unknown
-
2007
- 2007-07-30 JP JP2009524158A patent/JP5336372B2/ja not_active Expired - Fee Related
- 2007-07-30 PL PL07788029T patent/PL2049566T3/pl unknown
- 2007-07-30 US US12/310,003 patent/US7893019B2/en active Active
- 2007-07-30 WO PCT/EP2007/057824 patent/WO2008017603A1/en not_active Ceased
- 2007-07-30 AT AT07788029T patent/ATE453666T1/de not_active IP Right Cessation
- 2007-07-30 DE DE602007004120T patent/DE602007004120D1/de active Active
- 2007-07-30 EP EP07788029A patent/EP2049566B1/en active Active
- 2007-07-30 CA CA002660615A patent/CA2660615A1/en not_active Abandoned
- 2007-07-30 ES ES07788029T patent/ES2338605T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2660615A1 (en) | 2008-02-14 |
| US7893019B2 (en) | 2011-02-22 |
| ATE453666T1 (de) | 2010-01-15 |
| DE602007004120D1 (de) | 2010-02-11 |
| ITMI20061624A1 (it) | 2008-02-12 |
| WO2008017603A1 (en) | 2008-02-14 |
| US20100029555A1 (en) | 2010-02-04 |
| JP2010500390A (ja) | 2010-01-07 |
| JP5336372B2 (ja) | 2013-11-06 |
| EP2049566B1 (en) | 2009-12-30 |
| EP2049566A1 (en) | 2009-04-22 |
| ES2338605T3 (es) | 2010-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ITMI20061624A1 (it) | Mono-coniugati sito-specifici di g-csf | |
| EP3211001A3 (en) | Superagonists and antagonists of interleukin-2 | |
| UA103221C2 (uk) | Стабільний склад рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини | |
| EP2626427A3 (en) | Sirna conjugate and preparation method thereof | |
| ATE468862T1 (de) | G-csf konjugate | |
| BRPI0508424A (pt) | muteìnas de interleucina-2 melhoradas | |
| MY151184A (en) | A polypeptide complex comprising non-peptidyl polymer having three functional ends | |
| BR112013010127A2 (pt) | polipeptídeo agonista da interleucina 2, proteína de fusão, composição farmacêutica útil na terapia do câncer e enfermidades infecciosas crônicas, uso do polipeptídeo e uso da proteína de fusão | |
| CY1118073T1 (el) | Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης | |
| EP2810661A3 (en) | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids | |
| MX2011009281A (es) | Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 24p4c12. | |
| MY150739A (en) | Four branched dendrimer-peg for conjugation to proteins and peptides | |
| EP4640280A3 (en) | Cytotoxicity targeting chimeras for ccr2-expressing cells | |
| BR0312365A (pt) | Meio de cultura autólogo de células-mães progenitoras autólogas humanas, métodos para a preparação do mesmo e de uma composição de células-mães progenitoras autólogas humanas e para a obtenção de células-mães progenitoras musculares autólogas humanas, emprego de um meio de cultura autólogo de células-mães progenitoras autólogas humanas, procedimento para a obtenção de células-mães progenitoras musculares autólogas humanas e procedimento terapêutico de cardiomioplastia celular autóloga, composição enriquecida com células-mães progenitoras musculares autólogas humanas e composição farmacêutica | |
| MX2024010317A (es) | Quimeras dirigidas a la citotoxicidad para celulas que expresan el receptor 2 de quimiocinas c-c | |
| KR100735784B1 (ko) | 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물 | |
| ATE332377T1 (de) | P450 / acetaminophen gdept zur krebsbehandlung | |
| Kurzrock | Thrombopoietic factors in chronic bone marrow failure states: the platelet problem revisited | |
| WO2006010084A3 (en) | A system for delivering therapeutic agents into living cells and cell nuclei | |
| Bradstock | The use of hematopoietic growth factors in the treatment of acute leukemia | |
| Platter et al. | Lymphokines and monokines in the clinic | |
| Sergi et al. | Enzymatic techniques for PEGylation of biopharmaceuticals | |
| RU2012105766A (ru) | МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ ШИРОКИЙ СПЕКТР ЛИГАНДОВ ErbB И СПОСОБЫ ИХ ПРИГОТОВЛЕНИЯ И ИСПОЛЬЗОВАНИЯ | |
| CN1911447A (zh) | 转铁蛋白－聚乙二醇－药物分子复合物及其用途 | |
| Valent et al. | Why clinicians should be interested in interleukin-3 |